Krystal Biotech, Inc. reported fourth‑quarter and full‑year 2025 results that surpassed analyst expectations. Revenue for the quarter was $107.1 million, driven by sales of its flagship product VYJUVEK, and the company posted earnings per share of $1.70, a $0.12 or 7.6% beat over the consensus estimate of $1.58‑$1.61. Cash and investments at year‑end totaled $955.9 million, giving the company a strong liquidity cushion as it continues to fund its seven clinical‑stage programs.
VYJUVEK revenue of $107.1 million represented a 17% increase from the $91.1 million recorded in Q4 2024 and a 3.7% rise from the $104.5 million forecasted by analysts. The company’s cumulative U.S. sales since launch reached $730.3 million, underscoring the product’s growing market penetration. The revenue beat was modest, as consensus estimates ranged from $106.16 million to $107.4 million, placing the actual figure slightly above expectations but below the higher estimate of $108.61 million cited in the original article.
The earnings beat can be attributed to disciplined cost management and a favorable product mix. Krystal maintained a gross margin of 94% for both the quarter and the full year, reflecting pricing power and efficient manufacturing. Operating expenses were kept in line with guidance, and the company’s R&D and SG&A spend for 2026 is expected to fall between $175 million and $195 million, indicating continued investment in pipeline development while preserving profitability.
Krystal’s management highlighted the broader strategic context of the results. Chairman and CEO Krish S. Krishnan said, "In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact." He added, "As we work toward our goal of launching multiple products and treating more than 10,000 patients living with rare diseases by the end of 2030, our recent cystic fibrosis readout further reinforces the versatility of our platform in high‑turnover epithelial tissues." He concluded, "We believe we are still in the early stages of unlocking the transformational potential of our redosable HSV‑1‑based gene delivery platform, and we look forward to multiple registrational study readouts ahead across our rare disease pipeline."
Krystal is also advancing its pipeline with FDA Regenerative Medicine Advanced Therapy designation for KB707 in advanced NSCLC and Fast Track designation for KB111 in Hailey‑Hailey disease, positioning the company for future growth beyond VYJUVEK. The company’s global expansion continues with launches in Germany, France, and Japan, and pricing negotiations in Europe are underway, which could further boost international revenue in the coming quarters.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.